Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.

T. Ohnoshi, S. Hiraki, N. Ueda, M. Fujii, K. Machida, H. Ueoka, S. Kawahara, A. Kozuka, K. Kiura, T. Moritaka

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

Original languageEnglish
Pages (from-to)357-361
Number of pages5
JournalActa medica Okayama
Volume45
Issue number5
Publication statusPublished - Oct 1991

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer.'. Together they form a unique fingerprint.

  • Cite this

    Ohnoshi, T., Hiraki, S., Ueda, N., Fujii, M., Machida, K., Ueoka, H., Kawahara, S., Kozuka, A., Kiura, K., & Moritaka, T. (1991). Phase II study of ifosfamide, cisplatin, and vindesine combination in advanced non-small cell lung cancer. Acta medica Okayama, 45(5), 357-361.